Article Text

Download PDFPDF
Etanercept in treatment of Felty’s syndrome
  1. A Ghavami,
  2. S Genevay,
  3. T Fulpius,
  4. C Gabay
  1. Division of Rheumatology, Geneva University Hospital, Switzerland
  1. Correspondence to:
    Professor C Gabay
    Division of Rheumatology, Geneva University Hospital, 26 av. Beau-Séjour, 1211 Genève 14, Switzerland;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Felty’s syndrome (FS) is an uncommon extra-articular manifestation of rheumatoid arthritis (RA). It is more prevalent among women around 60 with a long history of severe articular disease, positive rheumatoid factor, and who carry the HLA-DR4 allele.1 Felty’s syndrome has a poor prognosis, with an increased mortality due to a higher incidence of severe infection.2 We describe a patient with seropositive, erosive RA and history of extra-articular manifestations, including vasculitis and FS. Treatment with etanercept gradually decreased the neutrophil count over 20 months. Discontinuation of etanercept and initiation of methotrexate was followed by a dramatic and sustained improvement of neutrophil count.


A 75 year old white woman with a 19 year history of seropositive RA with extra-articular manifestations including mononeuritis multiplex (1998) and at least a 4 year history of …

View Full Text